Categories
Uncategorized

Infectious Diseases Society of America Guidelines on the Treatment and Management of Patients with COVID-19

Summary: IDSA has developed evidence-based guidelines to support clinicians and other health-care professionals in their decisions about the treatment and management of patients with COVID-19. In this document, readers can find information on the results of studies and rationale for each recommendation, clinical experience, and references to additional sources. Therapies covered include hydroxychloroquine +/- azithromycin, lopinavir/ritonavir, corticosteroids, tocilizumab, and convalescent plasma.

Information current as of 4/11/2020

Organization: Infectious Diseases Society of America

Title: Infectious Diseases Society of America Guidelines on the Treatment and Management of Patients with COVID-19

Web Link: Read more here!

Categories
Uncategorized

Expert U.S. panel develops NIH treatment guidelines for COVID-19

Summary: A panel of U.S. experts has developed treatment guidelines for COVID-19. The document provides background information about each pharmacologic therapy (antivirals, host modifiers, and immune-based therapies) —such as clinical data about its use, ongoing clinical trials, and known interactions with other drugs. Importantly, the guidelines state that no COVID-19 medication has been conclusively shown to be safe and effective, but they do recommend against the use of hydroxychloroquine plus azithromycin (toxicity potential), lopinavir/ritonavir or other HIV protease inhibitors (pharmacodynamics and negative clinical trial data), interferons (suspected lack of efficacy and toxicity), and Janus kinase inhibitors (immunosuppression).

Information current as of 04/21/2020

Organization: National Institutes of Health (NIH)

Title: Expert U.S. panel develops NIH treatment guidelines for COVID-19

Web Link: Read more here!

Categories
Uncategorized

FDA Issues Emergency Use Authorization for Potential COVID-19 Treatment

Summary: The United States Food and Drug Administration has issued emergency use authorization for the investigational antiviral drug remdesivir for the treatment of suspected or laboratory-confirmed COVID-19 in adults and children. This authorization came just two days after an interim analysis of the NIAID-sponsored Adaptive COVID-19 Treatment Trial (ACTT) showed patients receiving remdesivir had a 31% reduced time to recovery compared to patients receiving placebo (p<0.001).

Information current as of 05/01/2020

Organization: Food and Drug Administration (FDA)

Title: FDA Issues Emergency Use Authorization for Potential COVID-19 Treatment

Web Link: Read more here!

Categories
Uncategorized

NIH clinical trial shows Remdesivir accelerates recovery from advanced COVID-19

Summary: Hospitalized patients with severe COVID-19 who received remdesivir recovered 31% faster than those who received placebo (median time to recovery was 11 days vs. 15 days), according to an interim analysis from a randomized, controlled trial of 1,063 patients. Sponsored by the National Institute of Allergy and Infectious Diseases (NIAID), this is the first clinical trial launched in the United States to evaluate an experimental treatment for COVID-19. There was also a statistically non-significant survival benefit, with a mortality rate of 8.0% in patients receiving remdesivir vs. a mortality rate of 11.6% in patients receiving placebo (p=0.059).

Information current as of 04/29/2020

Organization: National Institutes of Health (NIH)

Title: NIH clinical trial shows Remdesivir accelerates recovery from advanced COVID-19

Web Link: Read more here!

Categories
Uncategorized

Assessment of Evidence for COVID-19-Related Treatments

Summary: ASHP has compiled available evidence on antiviral agents, supporting agents, and related medications for their use in treating COVID-19. In this document, readers can find information on the results of studies, clinical experience, doses used, and references to additional sources.

Updates: On May 15, 2020, updates were posted to the following sections: Remdesivir, Corticosteroids (general), Methylprednisolone (DEPOMedrol®, SOLUMedrol®), Sarilumab (Kefzara®), Tocilizumab (Actemra®), and Nitazoxanide.

Organization: American Society of Health-System Pharmacists (ASHP)

Title: Assessment of Evidence for COVID-19-Related Treatments

Web Link: Read more here!